Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BMS, Tekmira expand RNA pact
July 2011
SHARING OPTIONS:

BURNABY, British Columbia—Bristol- Myers Squibb Co. (BMS) and Tekmira Pharmaceuticals have expanded their multi-year collaboration to include Tekmira's proprietary, newly developed lipid nanoparticle formulations for delivering to tumors as well as tissues outside the liver. The companies will also expand ongoing target validation work. Per the terms of the original agreement, BMS is utilizing small interfering RNA (siRNA) molecules created by Tekmira in LNPs in order to silence genes, conducting preclinical work to validate certain genes' functions and sharing data with Tekmira. The agreement grants BMS a first right to negotiate a licensing agreement on specific RNAi products that Tekmira has developed resulting from gene targets BMS has validated. In addition, Tekmira received $3 million as a result of the agreement. Dr. Mark J. Murray, Tekmira 's president and CEO, said in a press release that "the new work also includes additional cellular targets that were beyond the scope of the original agreement," adding that "Bristol-Myers Squibb will continue to share the data from this research with Tekmira."


Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.